Capstone Therapeutics Corporation has announced a significant financial agreement involving the issuance of senior secured convertible notes to an institutional investor. The total principal amount of these notes is set at $10,909,885, with an 8.34% original issue discount. Initially, a Convertible Note worth approximately $3,272,966 was issued, convertible into shares of Capstone's common stock at a conversion price of $1.72 per share. However, as of August 15, 2025, the company and the investor mutually agreed to adjust the conversion price to $1.00 per share. This adjustment allows conversion up to a principal amount of $1,363,736 under the new terms. This strategic move is expected to enhance the investor's ability to convert the notes and potentially increase the liquidity of Capstone's common stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.